In the context of endometriosis treatment, targeting partial suppression of the hypothalamus-pituitary-gonadal (HPG) axis through kisspeptin or neurokinin B antagonists could maintain therapeutic efficacy while avoiding drawbacks associated with GnRH. This evidence concerns the gene KISS1 and endometriosis.